Table 2.

Unique UPRs induced by CPA in GL261(B6) compared to LLC and B16F10 tumors. Shown are the 47 UPRs unique to CPA-treated GL261(B6) tumors identified in Additional file 4: Table S3G, classified into 4 categories based on their functions. Group 1 UPRs are expected to contribute to the anti-tumor response, group 2 UPRs counter the anti-tumor response, and the actions of group 3 UPRs depend on cell context. Only two of the UPRs are associated with the glioma-specific lineage of GL261 tumors (group 4)

Category	Reported function	Predicted activation state	Molecule type	Upstream regulator
1. Facilitate tumor regression by immune-mediated mechanisms or by inhibiting tumor cell survival	Activate immune responses	Activated	Cytokine	IL12 (complex), IL7,IL12A,IL12B,CCL11
			Enzyme	TRAF6
			Kinase	MAPK8,MAPKAPK2,MAP3K14,RIPK2
			Other	MOG,TAC1
			Transcription regulator	TBX21,HMGB1,IRF6,HOXA7
			Transmembrane receptor	TLR2,TYROBP,CD2,CD14,OLR1,CD86,BTNL2
	Inhibit immune responses	Inhibited	Transcription regulator	PRDM1
			Neurohormone	CORT
			Phosphatase	DUSP1
	Promote tumor cell survival	Inhibited	Enzyme	SCD
			Growth factor	WISP2
			Kinase	PRKAA1
			Mature microRNA	miR-155-5p (miRNAs w/seed UAAUGCU)
			Transcription regulator	MAX,BCL3
2. Counter tumor regression	Inhibit immune respones	Activated	Enzyme	PTGS2
	Promote tumor cell survival	Activated	Enzyme	FN1
			Kinase	FGFR2
3. Postive or negatve regulator of immune response, depending on cell context	Activate or inhibit immunity	Activated	Cytokine	CSF2,CXCL8,PF4
			G-protein coupled receptor	CCR5
			Apoptotic factor	TRADD
	Activate or inhibit immunity	Inhibited	Enzyme	TAB1
			Kinase	MTOR
			Other	PTX3
			Transcription regulator	IRF4
			Transporter	APOA1
4. Glioma cell lineage	Brain development	Activated	Transcription regulator	SIM1,PAX7